Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen sales and marketing update

Stronger sales, margin increases and tax law changes enabled AMGN to increase its EPS to 72 cents in the third quarter ended Sept. 30, from 60

Read the full 264 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE